Value Proposition of Personalized Medicine

John Hennessy, CMPE

John Hennessy discusses the benefits of the “personalized medicine toolkit” to help make better decisions

Related Videos

January 20, 2016

Pathways to a Cancer Stem Cell

Dr Wainberg expands upon what makes these types of cells unique.

March 31, 2015

Ibrutinib and ABT199 for CLL

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.